Evolution of Hydrogen Sulfide Therapeutics to Treat Cardiovascular Disease. Issue 5 (17th August 2018)

• Record Type: Journal Article
• Authors: Li, Zhen; Polhemus, David J.; Lefer, David J.
• Is Part Of: Circulation research. Volume 123:Issue 5(2018)
• Publication Date: 2018-08-17
• Subjects: animals -- cardiovascular diseases -- nitric oxide; Cardiovascular system -- Periodicals; Blood -- Circulation -- Periodicals; Blood Circulation; Cardiovascular System; Vascular Diseases; Sang -- Circulation -- Périodiques; Appareil cardiovasculaire -- Périodiques; 612.1
• DOI: 10.1161/CIRCRESAHA.118.311134
• Languages: English
• ISSNs: 0009-7330

Abstract

Abstract : Hydrogen sulfide (H2 S)—a potent gaseous signaling molecule—has emerged as a critical regulator of cardiovascular homeostasis. H2 S is produced enzymatically by 3 constitutively active endogenous enzymes in all mammalian species. Within the past 2 decades, studies administering H2 S-donating agents and the genetic manipulation of H2 S-producing enzymes have revealed multiple beneficial effects of H2 S, including vasodilation, activation of antiapoptotic and antioxidant pathways, and anti-inflammatory effects. More recently, the heightened enthusiasm in this field has shifted to the development of novel H2 S-donating agents that exert favorable pharmacological profiles. This has led to the discovery of novel H2 S-mediated signaling pathways. This review will discuss recently developed H2 S therapeutics, introduce signaling pathways that are influenced by H2 S-dependent sulfhydration, and explore the dual-protective effect of H2 S in cardiorenal syndrome.